Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight'

Biomerieux SA

09/05/2024 08:36

** Barclays initiates coverage of DiaSorin  DIAS.MI  with
"equal weight", seeing its top-line 9% CAGR revenue estimate for
2024-27 to be in line with the company's mid-term guidance and
driven by the launch of new products
    ** However, the Italian diagnostic group's margin targets
are "ambitious", as the company already has attractive margins
in comparison to its peers, and its focus on cost management is
"historically strong", the brokerage notes
    ** Barclays still has a preference for French peer
bioMerieux  BIOX.PA , trading at a similar multiple, as it
offers fewer risks in its mid-term targets
    ** Out of 15 analysts covering DiaSorin, six rate it "strong
buy"/"buy", ​four "hold", and three "strong sell"/"sell"

 (Philippe Leroy Beaulieu)
 ((Philippe.leroybeaulieu@tr.com))